Avadel Pharmaceuticals’ (AVDL) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright restated their buy rating on shares of Avadel Pharmaceuticals (NASDAQ:AVDL) in a research note issued to investors on Tuesday morning,Benzinga reports. HC Wainwright currently has a $21.00 target price on the stock. HC Wainwright also issued estimates for Avadel Pharmaceuticals’ Q3 2025 earnings at $0.01 EPS and Q4 2025 earnings at $0.12 EPS.

Several other equities analysts have also commented on AVDL. Piper Sandler cut their price target on Avadel Pharmaceuticals from $24.00 to $13.00 and set an “overweight” rating on the stock in a research note on Friday, January 10th. Deutsche Bank Aktiengesellschaft initiated coverage on shares of Avadel Pharmaceuticals in a research report on Tuesday, February 11th. They set a “buy” rating and a $12.00 target price on the stock. UBS Group reduced their price target on shares of Avadel Pharmaceuticals from $22.00 to $14.00 and set a “buy” rating for the company in a report on Monday, January 13th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $19.00 price objective on shares of Avadel Pharmaceuticals in a research note on Monday. Eight analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $19.88.

Avadel Pharmaceuticals Stock Up 0.1 %

AVDL opened at $7.88 on Tuesday. Avadel Pharmaceuticals has a 52-week low of $7.39 and a 52-week high of $19.09. The business has a fifty day moving average of $8.67 and a 200 day moving average of $11.45. The stock has a market cap of $759.33 million, a P/E ratio of -9.97 and a beta of 1.28.

Insider Buying and Selling

In other Avadel Pharmaceuticals news, Director Geoffrey Michael Glass bought 20,279 shares of the company’s stock in a transaction that occurred on Tuesday, December 10th. The shares were purchased at an average cost of $9.84 per share, for a total transaction of $199,545.36. Following the purchase, the director now directly owns 75,904 shares in the company, valued at $746,895.36. This represents a 36.46 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CFO Thomas S. Mchugh purchased 5,000 shares of the stock in a transaction on Wednesday, December 11th. The stock was acquired at an average cost of $10.49 per share, with a total value of $52,450.00. Following the acquisition, the chief financial officer now owns 85,500 shares of the company’s stock, valued at approximately $896,895. This represents a 6.21 % increase in their position. The disclosure for this purchase can be found here. Insiders bought a total of 42,981 shares of company stock worth $400,005 in the last 90 days. 4.80% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. FMR LLC acquired a new stake in shares of Avadel Pharmaceuticals during the third quarter worth $31,000. Advisors Asset Management Inc. raised its stake in Avadel Pharmaceuticals by 56.1% in the 3rd quarter. Advisors Asset Management Inc. now owns 7,921 shares of the company’s stock worth $104,000 after acquiring an additional 2,846 shares during the last quarter. Hsbc Holdings PLC acquired a new stake in Avadel Pharmaceuticals during the 4th quarter worth about $113,000. Kazazian Asset Management LLC purchased a new stake in Avadel Pharmaceuticals during the 4th quarter valued at about $126,000. Finally, Aigen Investment Management LP purchased a new stake in Avadel Pharmaceuticals during the 3rd quarter valued at about $160,000. Institutional investors and hedge funds own 69.19% of the company’s stock.

Avadel Pharmaceuticals Company Profile

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017.